Aging individuals succumb most frequently to vascular compromise, among various other complications. Diabetic patients suffer from a similar spectrum of problems, which, although mostly unrelated to insulin deficiency, have been clearly associated with hyperglycemia. The investigators have developed the central hypothesis that aging and diabetic complications are in part due to the covalent modification of tissue proteins by ambient glucose, forming time-stable adducts termed Advanced Glycosylation Endproducts (AGE). These irreversible reactive adducts increase linearly with age and at an accelerated rate in patients with diabetes. A macrophage receptor system specific for the removal of AGEs on senescent proteins and cells has been identified and characterized over the past 5 years. Ingestion and degradation of AGE-proteins by macrophages is followed by the synthesis of a host of cytokines and growth factors, suggesting a mechanism by which macrophages participate in tissue repair via this system. The AGE-receptor system appears to consist of two AGE-binding proteins, a 60 kD and a 90 kD, which have been purified and partially sequenced. Cellular aging and insulin excess have been identified as two important factors associated with a compromise in the efficiency of the macrophage receptors, possibly contributing to the acceleration of vascular dysfunction and hypertension associated with both aging and hyperinsulinemia. The objectives of the current proposal are: 1. To clone and sequence the genes of both AGE-receptor binding units, and to develop monoclonal antibodies, so as to proceed with the molecular and cell biology studies of the system, 2. To explore the regulation of expression and function of each AGE-binding protein at the mRNA and protein levels in response to various in vivo physiological and pathological states associated with Aging and Diabetes. 3. To study, the in vivo effects AGE accumulation in the vessels and kidney, two tissues which play a central role in the hypertension of diabetes and aging, using a novel AGE-animal model.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG006943-07
Application #
3118071
Study Section
Pathology A Study Section (PTHA)
Project Start
1987-02-01
Project End
1997-06-30
Budget Start
1993-07-05
Budget End
1994-06-30
Support Year
7
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Picower Institute for Medical Research
Department
Type
DUNS #
City
Manhasset
State
NY
Country
United States
Zip Code
11030
Li, J J; Dickson, D; Hof, P R et al. (1998) Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis. Mol Med 4:46-60
Koschinsky, T; He, C J; Mitsuhashi, T et al. (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94:6474-9
Stitt, A W; Li, Y M; Gardiner, T A et al. (1997) Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 150:523-31
Stitt, A W; He, C; Friedman, S et al. (1997) Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med 3:617-27
Fishbane, S; Bucala, R; Pereira, B J et al. (1997) Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney Int 52:1645-50
Li, Y M; Steffes, M; Donnelly, T et al. (1996) Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci U S A 93:3902-7
Li, Y M; Mitsuhashi, T; Wojciechowicz, D et al. (1996) Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci U S A 93:11047-52
Bucala, R; Vlassara, H (1995) Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 26:875-88
Zimmerman, G A; Meistrell 3rd, M; Bloom, O et al. (1995) Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci U S A 92:3744-8
Vlassara, H; Li, Y M; Imani, F et al. (1995) Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1:634-46

Showing the most recent 10 out of 22 publications